Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib.
Ondrej FialaPavel OstašovAneta RozsypalováMilan HoraOndřej ŠorejsJan ŠustrBarbora BendováIvan TrávníčekJan FilipovskýJindřich FínekTomas BuchlerPublished in: Cancer management and research (2021)
The present study results suggest that the use of metformin was associated with favorable outcome of mRCC patients treated with sunitinib or pazopanib.
Keyphrases